EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Outcome of People with Parkinson’s Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa

Diego Santos García iD, Inés Legarda, Tamara M González Fernández, Ana Rodríguez Sanz, Maria Isabel Morales-Casado, Alejandro Peral, Nuria Caballol, María Álvarez Sauco, Iria Campos Rodríguez iD, Déborah Alonso Modino, Lydia López Manzanares iD, Jesús Olivares Romero und 1 weitere

Brain Sciences · 22.03.2026 · 16 (3) · 343

DOI: 10.3390/brainsci16030343 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Brain Sciences, online erschienen am 22.03.2026. Verfasst von Diego Santos García und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Hospital Universitario de A Coruña (HUAC), Complejo Hospitalario Universitario de A Coruña (CHUAC), C/As Xubias 84, 15006 A …. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The clinical outcome of switching to levodopa-entacapone-carbidopa intestinal gel (LECIG) after failure of subcutaneous foslevodopa/foscarbidopa (fLD/fCD) is unknown. We analyze it in people with Parkinson’s disease (PwP) treated in Spain.

Methods

Retrospective analysis of PwP who had previously received fLD/fCD but dropped out for different reasons and started before this LECIG in Spain up to 30 November 2025. Non-parametric tests were applied to evaluate the changes between the pre- (Vpre) and post-treatment (Vpost) (LECIG) periods.

Results

Data about 14 patients (57.1% males; 66.6 ± 8.6 years old) from 12 hospitals out of a total of 15 who were treated with LECIG were included. The mean time with fLD/fCD was 98.6 ± 92.3 days, with 92.9% and 57.1% experiencing side effects and lack of response, respectively. Specifically, significant subcutaneous nodules were reported in up to 64.3% of the patients. LECIG was a direct switch from fLD/fCD in 35.7% of the patients. LECIG was well tolerated, with only one dropout due to complications related to dementia. Adverse events were reported in 28.6% and 35.7% of the patients in the optimization and final follow-up evaluation (mean follow-up of 233.7 ± 157.4 days) phases, respectively. From Vpre to Vpost, “Off” time was reduced in 2.9 ± 1.9 h (p = 0.002) and motor symptoms burden improved significantly (p = 0.013), whereas a trend of significance was found for non-motor symptoms burden (p = 0.050) and quality of life (p = 0.126).

Conclusions

LECIG could be an alternative therapeutic option in PwP who failed fLD/fCD.

Schlagwörter

Stichwörter der Autor:innen

Parkinson’s diseaseeffectivenessfoslevodopa/foscarbidopalevodopa-entacapone-carbidopasafety

Autor:innen und Institutionen

  • Department of Neurology, Hospital Universitario de A Coruña (HUAC), Complejo Hospitalario Universitario de A Coruña (CHUAC), C/As Xubias 84, 15006 A Coruña, Spain.
  • Grupo de Investigación en Enfermedad de Parkinson y otros Trastornos del Movimiento, INIBIC (Instituto de Investigación Biomédica de A Coruña), 15006 A Coruña, Spain.
  • Hospital San Rafael, 15006 A Coruña, Spain.
  • Fundación Degen, 15004 A Coruña, Spain.
  • Hospital Son Espases, 07120 Palma de Mallorca, Spain.
  • Hospital del Bierzo, 24404 Ponferrada, Spain.

ORCID-Profile: Diego Santos García, Iria Campos Rodríguez, Lydia López Manzanares

Zitieren

APA

Santos García, D., Legarda, I., González Fernández, T. M., Rodríguez Sanz, A., Morales-Casado, M. I., Peral, A., Caballol, N., Álvarez Sauco, M., Campos Rodríguez, I., Alonso Modino, D., López Manzanares, L., Olivares Romero, J., & Blanco Ollero, A. (2026). Outcome of People with Parkinson’s Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa. Brain Sciences, 16(3), 343. https://doi.org/10.3390/brainsci16030343

Vancouver

Santos García D, Legarda I, González Fernández TM, Rodríguez Sanz A, Morales-Casado MI, Peral A, et al. Outcome of People with Parkinson’s Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa. Brain Sciences. 2026;16(3):343. doi:10.3390/brainsci16030343

BibTeX
@article{SantosGarca2026,
  author = {Santos García, Diego and Legarda, Inés and González Fernández, Tamara M and Rodríguez Sanz, Ana and Morales-Casado, Maria Isabel and Peral, Alejandro and Caballol, Nuria and Álvarez Sauco, María and Campos Rodríguez, Iria and Alonso Modino, Déborah and López Manzanares, Lydia and Olivares Romero, Jesús and Blanco Ollero, Alberto},
  title = {Outcome of People with Parkinson’s Disease Treated with Levodopa-Entacapone-Carbidopa Intestinal Gel Who Failed Previous Subcutaneous Foslevodopa/Foscarbidopa},
  journal = {Brain Sciences},
  year = {2026},
  volume = {16},
  number = {3},
  pages = {343},
  doi = {10.3390/brainsci16030343}
}
Kostenlos starten →